Product overview
FOXO4-DRI 10mg/10vials is a sterile lyophilized research peptide. FOXO4-DRI was developed by the Peter de Keizer lab and published in Cell (2017) as a tool peptide for the selective elimination of senescent cells. The molecule is a D-retro-inverso (DRI) peptide — synthesized with D-amino acids in reverse sequence — derived from the interaction interface between FOXO4 and p53, designed to disrupt that interaction selectively in senescent cells.
Independently assayed by HPLC and MS, and lot-traceable to the source preparation.
Typical research dose range
Published preclinical senolytic protocols using FOXO4-DRI in mouse models have typically used intraperitoneal administration at quantities in the range of 5 mg/kg every other day across multi-week cycles. Researchers should consult the original Cell 2017 paper and follow-on senolytic literature when designing protocols.
Stack and pairing
FOXO4-DRI is one of the canonical tool peptides in preclinical senolytic and longevity research. It is frequently studied alongside Epithalon (telomerase-activity work), NAD+ (cellular bioenergetics), and SS-31 (mitochondrial oxidative stress) in multi-arm aging-axis study designs.
Reconstitution and storage
Reconstitute each vial with 1-2 mL of bacteriostatic water for the target working concentration. Use sterile technique. Once reconstituted, store at 2-8 °C and use within 30 days for best stability.
Lyophilized vials should be kept refrigerated at 2-8 °C until first use. For long-term storage beyond six months, store at -20 °C in the original sealed vial. Avoid repeated freeze-thaw cycles.
Kit contents
- 10 × 10mg vials of lyophilized FOXO4-DRI
- 1 × certificate of analysis (lot-specific)
- 1 × handling and reconstitution insert
